 |
市场调查报告书
商品编码
1812612
美国的医药品的药价设定与给付:资料为基础分析Pricing and Reimbursement of Pharmaceuticals in the US: A Data-Driven Analysis |
||||||
本报告对美国药品定价与报销进行了深入的数据驱动分析，重点关注联邦医疗保险 (Medicare) D 部分和医疗补助 (Medicaid)。报告利用 2011 年至 2023 年的支出、处方和理赔数据，检视了这两个系统的趋势，并详细回顾了 2023 年联邦医疗保险 D 部分报销排名前 50 位的品牌药品。
深入了解支出模式、处方量和理赔指标的波动、联邦医疗保险 (Medicare) 和医疗补助 (Medicaid) 报销的差异，以及近期政策变化（例如《降低通货膨胀法案》和 2025 年行政命令）对高价药品定价和谈判的影响。
关键问题
- 1. Medicare D 部分和 Medicaid 药品定价和报销的当前趋势。
- 2.包括《通货膨胀削减法案》和 2025 年行政命令在内的近期政策如何影响高价药品的定价和报销？
- 3.2023 年 Medicare D 部分报销前 50 名的药品的支出模式。
- 4.前 50 名的药品的处方量和申请人指标有何变化？
- 5.Medicare D 部分和 Medicaid 药品报销之间的主要区别是什么？
- 6.不同药品和治疗领域的每张处方支出和每位申请人的支出如何比较？
- 7.製造商返利和价格优惠如何影响支出资料的解读？
- 8.透过即将到来的医疗保险药品价格谈判，预计美国药品定价和报销将出现哪些趋势？
主要企业
|
|
|
调查手法
本报告是基于独立而简洁的分析，这些分析源自于专有的产业研究以及对产业意见领袖的深入访谈。报告深入分析了製药企业高管需要了解的关键发展和市场趋势，以应对未来的机会和课题。每份报告的重点都基于对二手文献的回顾和已发现的知识缺口。基于这项初步研究，我们制定了基于证据的讨论指南，并融入专家意见，以确保研究能够解答最重要的问题。此外，我们采用严格的筛选标准，以确保受访者拥有就该主题发言的经验、知识和资格。
我们报告的特点
FirstWord Reports 是值得信赖的行业领导者，专注于製药业，为生物製药专业人士和决策者提供深入、可操作的洞察。我们深厚的行业知识使我们能够提供相关且有价值的洞察，帮助我们的客户掌握新兴趋势，并有效应对复杂的课题。凭藉广泛的研究以及来自顶尖专家和关键意见领袖的独立、公正的见解，我们的报告能够提供您所需的准确性和可靠性。独家访问独家访谈和数据，以及持续的市场监测，确保全面了解市场动态。我们的报告涵盖 40 多个动态疾病领域、包括 KOL 洞察和定量医生调查在内的医生情报以及行业专家对医疗事务、数位健康、销售和营销、市场准入和其他领域问题的看法，使您能够做出更明智的、数据驱动的决策，并在快速变化的行业中保持竞争力。
This report provides a detailed, data-driven analysis of pharmaceutical pricing and reimbursement in the US, focusing on Medicare Part D and Medicaid. Drawing on 2011-2023 expenditure, prescription and claimant data, it examines trends across both programs and offers an in-depth review of the top 50 branded drugs reimbursed under Medicare Part D in 2023.
Gain insight into expenditure patterns, variations in prescription volumes and claimant metrics, differences between Medicare and Medicaid reimbursement and the implications of recent policy developments, including the Inflation Reduction Act and the 2025 Executive Order, on high-cost drug pricing and negotiation.
Key Questions Answered:
- 1. What are the current trends in pharmaceutical pricing and reimbursement under Medicare Part D and Medicaid?
- 2. How has recent policy, including the Inflation Reduction Act and 2025 Executive Order, impacted high-cost drug pricing and reimbursement?
- 3. What are the expenditure patterns for the top 50 drugs reimbursed through Medicare Part D in 2023?
- 4. How do prescription volumes and claimant metrics vary among these top 50 drugs?
- 5. What are the key differences in drug reimbursement between Medicare Part D and Medicaid?
- 6. How do expenditure per prescription and per claimant compare across drugs and therapy areas?
- 7. How do manufacturer rebates and price concessions factor into the interpretation of expenditure data?
- 8. What are the projected trends in US pharmaceutical pricing and reimbursement through upcoming Medicare drug price negotiations?
Key Companies:
|
|
|
Methodology:
Dossier reports are developed from independent and concise analysis derived from original industry surveys and in-depth interviews with industry thought leaders. Reports analyse in detail significant developments and market trends that pharma executives need to understand if they are to manage the opportunities and challenges that lie ahead. The focus of each report is defined by a review of the secondary literature and any knowledge gaps identified. Based on this initial research, an evidence-based and expert-informed discussion guide is developed to ensure the research answers the most critical questions. Additionally, robust screening criteria are established to ensure that those interviewed are qualified in terms of their experience, knowledge and stature to speak on the topic.
What makes our reports different?
FirstWord Reports, a trusted industry leader with an exclusive focus on the pharmaceutical sector, delivers in-depth, actionable insights for biopharma professionals and decision-makers. Our deep industry knowledge enables us to provide relevant and valuable insights that help you identify emerging trends and navigate complex challenges effectively. Backed by extensive research and independent, impartial insights from leading experts and KOLs, our reports deliver the accuracy and reliability you need. With exclusive access to interviews and data unavailable elsewhere, along with ongoing market monitoring, we give you a comprehensive view of market dynamics. Covering over 40 dynamic disease areas and providing physician intelligence, including KOL insights and quantitative physician surveys, as well as industry expert views on issues in medical affairs, digital health, sales & marketing, market access, and other areas, our reports empower you to make smarter, data-driven decisions and maintain a competitive edge in a fast-moving industry.
全球药房配药市场规模（按配药类型、治疗领域、应用和地区划分）预测
通讯药品市场：按产品类型、按药品类型、按治疗领域、按类型、按服务模式、按最终用户、按地区
复合药房市场； - 2024 年至 2034 年全球产业分析、规模、份额、成长、趋势和预测按产品类型、治疗领域、应用和地区分類的配药市场
复合药房市场规模、份额和增长分析（按治疗领域、年龄组、类型、不孕性别和地区）- 行业预测 2025-2032
美国复合药房市场规模、份额和趋势分析报告：按类型、治疗领域、年龄组、复合类型、无菌性别、细分市场预测，2024-2030复合药局市场 - 分产品（口服、肠胃外、局部、眼科、鼻腔、直肠、耳科）治疗领域（疼痛管理、荷尔蒙替代）、应用、复合类型、无菌、配销通路、全球预测 2024 - 2032复合药房市场 - 全球行业规模、份额、趋势、机会和预测，按治疗领域、给药途径、最终用户（按地区和竞争）细分，2019-2029F
美国邮购药品市场规模和预测、国家和份额、趋势和成长机会分析覆盖范围：药物类型、产品和订购方式